专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2021080950A1 METHODS FOR TREATING A HEMATOLOGICAL CANCER AND THE USE OF COMPANION BIOMARKERS FOR 2-(2,6-DIOXOPIPERIDIN-3-YL)-4-((2-FLUORO-4-((3-MORPHOLINOAZETIDIN-1-YL)METHYL)BENZYL)AMINO)ISOINDOLINE-1,3-DIONE 审中-公开
公开(公告)号：WO2021080950A1
公开(公告)日：2021-04-29
申请号：PCT/US2020/056431
申请日：2020-10-20
申请人： CELGENE CORPORATION
发明人： ANTON, Maria Soraya Carrancio , FONTANILLO, Celia Fontanillo , KASIBHATLA, Shailaja , LOPEZ-GIRONA, Antonia , LU, Gang , WANG, Kai
IPC分类号： C07D403/14 , C07D407/14 , A61P35/00
摘要： A method of identifying a subject having a hematological cancer who is likely to be responsive to a treatment compound, comprising administering the treatment compound to the subject having the hematological cancer; obtaining a sample from the subject; determining the level of a biomarker in the sample from the subject; and diagnosing the subject as being likely to be responsive to the treatment compound if the level of the biomarker in the sample of the subject changes as compared to a reference level of the biomarker; wherein the treatment compound is Compound 1, Compound 2, or Compound 3.

2. 发明申请

WO2017053763A3 ANDROGEN RECEPTOR VARIANT 7 AS A BIOMARKER FOR TREATMENT SELECTION IN PATIENTS WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER (mCRPC) 审中-公开
公开(公告)号：WO2017053763A3
公开(公告)日：2017-03-30
申请号：PCT/US2016/053387
申请日：2016-09-23
申请人： EPIC SCIENCES, INC.
发明人： DITTAMORE, Ryan
IPC分类号： G01N33/574 , C12Q1/68
摘要： The present invention provides a method of identifying a metastatic castration resistant prostate cancer (mCRPC) patient with an improved response to taxane therapy compared to androgen receptor (AR) targeted therapy comprising (a) performing a direct analysis comprising immunofluorescent staining and morphological characterization of nucleated cells in a blood sample obtained from the patient to generate circulating tumor cell (CTC) data, wherein the analysis comprises detecting the presence of an Androgen Receptor Variant 7 (AR-V7) in said cells, and (c) evaluating the CTC data to identify a mCRPC patient with an improved response to taxane therapy compared to ARS-directed therapy therapy.

3. 发明申请

WO2015112999A1 DETECTION OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) EXPRESSION ON CIRCULATING TUMOR CELLS (CTC) 审中-公开
标题翻译：检测循环肿瘤细胞（CTC）前列腺特异性膜抗原（PSMA）表达
公开(公告)号：WO2015112999A1
公开(公告)日：2015-07-30
申请号：PCT/US2015/012957
申请日：2015-01-26
申请人： EPIC SCIENCES, INC.
发明人： DITTAMORE, Ryan
IPC分类号： G01N33/53
CPC分类号： G01N33/57434 , G01N2333/4742 , G01N2333/70589 , G01N2333/948 , G01N2800/52
摘要： The disclosure provides a method for detecting prostate specific membrane antigen (PSMA) on circulating tumor cells (CTCs) obtained from a patient afflicted with prostate cancer comprising (a) performing a direct analysis comprising immunofluorescent staining and morphological characterization of nucleated cells in a blood sample obtained from the patient to detect circulating tumor cells (CTC), and (b) determining the number of CTCs expressing PSMA. The disclosure also provides a provides a method for identifying a patient afflicted with prostate cancer as a candidate for PSMA targeted therapy comprising (a) performing a direct analysis comprising immunofluorescent staining and morphological characterization of nucleated cells in a blood sample obtained from the patient to detect circulating tumor cells (CTC), (b) determining prevalence of a CTC subpopulation expressing PSMA, and (c) comparing the prevalence of the CTC subpopulation expressing PSMA to a reference value, wherein the prevalence of the CTC subpopulation expressing PSMA above the reference value identifies the patient as a candidate for PSMA targeted therapy. The disclosure further provides a provides a method for predicting resistance to androgen receptor (AR) targeted therapy a patient afflicted with prostate cancer comprising (a) performing a direct analysis comprising immunofluorescent staining and morphological characterization of nucleated cells in a blood sample obtained from the patient to detect circulating tumor cells (CTC), (b) determining prevalence of a CTC subpopulation expressing PSMA, and (c) comparing the prevalence of the CTC subpopulation expressing PSMA to a reference value, wherein the prevalence of the CTC subpopulation expressing PSMA above the reference value is indicative of resistance to androgen receptor (AR) targeted therapy.
摘要翻译：本公开提供了一种用于检测从患有前列腺癌的患者获得的循环肿瘤细胞（CTC）上的前列腺特异性膜抗原（PSMA）的方法，包括（a）进行包括血液样品中有核细胞的免疫荧光染色和形态学表征的直接分析从患者获得以检测循环肿瘤细胞（CTC），和（b）确定表达PSMA的CTC的数量。本公开还提供了一种用于鉴定患有前列腺癌的患者作为PSMA靶向治疗的候选物的方法，其包括（a）进行包括免疫荧光染色和从患者获得的血液样品中的有核细胞的形态学表征的直接分析以检测循环肿瘤细胞（CTC），（b）确定表达PSMA的CTC亚群的患病率，和（c）将表达PSMA的CTC亚群的患病率与参考值进行比较，其中表达PSMA的CTC亚群的患病率高于参考值将患者识别为PSMA靶向治疗的候选者。本发明还提供了一种预测对患有前列腺癌的患者的雄激素受体（AR）靶向治疗的抗性的方法，包括（a）进行包括免疫荧光染色和从患者获得的血液样品中的有核细胞的形态学表征的直接分析检测循环肿瘤细胞（CTC），（b）确定表达PSMA的CTC亚群的流行率，和（c）将表达PSMA的CTC亚群的患病率与参考值进行比较，其中表达PSMA的CTC亚群的流行率高于参考值表示对雄激素受体（AR）靶向治疗的抗性。

4. 发明申请

WO2012088434A2 COMPOSITIONS RELATING TO A PHOSPHOPROTEIN AND METHODS OF USE 审中-公开
标题翻译：与磷酸二氢钙相关的组合物及其使用方法
公开(公告)号：WO2012088434A2
公开(公告)日：2012-06-28
申请号：PCT/US2011/066878
申请日：2011-12-22
申请人： SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE , JIANG, Zhen, Yue
发明人： JIANG, Zhen, Yue
IPC分类号： A61K38/02 , G01N33/53 , C12Q1/48 , C12N15/85 , A61K48/00 , A61P3/10 , A61P25/00 , C12N5/09 , A01K67/027 , A61K49/00
CPC分类号： G01N33/5011 , A01K67/0276 , A01K2217/075 , A01K2227/105 , A01K2267/0362 , A01K2267/0375 , A61K38/02 , A61K49/0008 , C12N15/8509 , G01N33/502
摘要： The invention provides methods and compositions for identifying agents that modulates 138-kDa C2 domain-containing phosphoprotein (CDP138) activity or phosphorylation levels both in vivo and in vitro . Also provided are methods and compositions to prolong the survival of neuronal cells, to ameliorate or prevent a condition associated with release of insulin from insulin producing cells and insulin-stimulated glucose metabolism, to inhibiting proliferation of a cancer cell and to inducing cell cycle arrest of a cancer cell.
摘要翻译：本发明提供用于鉴定在体内和体外调节含138-kDa C2结构域的磷蛋白（CDP138）活性或磷酸化水平的试剂的方法和组合物。还提供了延长神经细胞存活的方法和组合物，改善或预防与胰岛素产生细胞和胰岛素刺激的葡萄糖代谢释放胰岛素相关的病症，抑制癌细胞的增殖和诱导细胞周期停滞一个癌细胞。

5. 发明申请

WO2011103567A2 PEPTIDES AND METHODS FOR INDUCING CELL DEATH 审中-公开
标题翻译：诱导细胞死亡的肽和方法
公开(公告)号：WO2011103567A2
公开(公告)日：2011-08-25
申请号：PCT/US2011/025707
申请日：2011-02-22
申请人： LOS ANGELES BIOMEDICAL RESEARCH INSTITUTE AT HARBOR-UCLA MEDICAL CENTER , YEAMAN, Michael, R. , YOUNT, Nannette, Y.
发明人： YEAMAN, Michael, R. , YOUNT, Nannette, Y.
IPC分类号： A61K51/08
CPC分类号： C07K14/47 , A01N47/44 , A61K47/6415 , C07K14/005 , C07K14/4747 , C12N7/00 , C12N2795/10031
摘要： The invention provide isolated peptides, protides and conjugates having novel peptide sequences which are able to induce antimicrobial, anti-cancer, anti-inflammatory, anti-proliferative or programmed cell death activity. The invention also provides a method of inducing programmed cell death in a cell by contacting the cell with an isolated peptide, protide or conjugate described herein. In some aspects, the method can be used in the diagnosis, prevention, or treatment of a disease, such as an infection, cancer, autoimmune disease, or inflammatory disease.
摘要翻译：本发明提供具有能够诱导抗微生物，抗癌，抗炎，抗增殖或程序性细胞死亡活性的新肽序列的分离的肽，抗原和缀合物。本发明还提供了通过使细胞与本文所述的分离的肽，抗原或缀合物接触来诱导细胞中程序性细胞死亡的方法。在某些方面，该方法可用于诊断，预防或治疗诸如感染，癌症，自身免疫性疾病或炎性疾病的疾病。

6. 发明申请

WO2010090830A1 MODULATION OF SIRT1 EXPRESSION 审中-公开
标题翻译： SIRT1表达的调节
公开(公告)号：WO2010090830A1
公开(公告)日：2010-08-12
申请号：PCT/US2010/021478
申请日：2010-01-20
申请人： ISIS PHARMACEUTICALS, INC. , YALE UNIVERSITY , BHANOT, Sanjay , SHULMAN, Gerald , YU, Xing-xian
发明人： BHANOT, Sanjay , SHULMAN, Gerald , YU, Xing-xian
IPC分类号： A61K31/70 , C07K16/00
CPC分类号： A61K31/00 , A61K31/155 , A61K31/198 , A61K31/427 , A61K31/4453 , A61K31/7052 , A61K31/711 , A61K45/06 , C12N15/1137 , C12N2310/11 , C12N2310/315 , C12N2310/321 , C12N2310/3231 , C12N2310/3341 , C12N2310/341 , C12N2310/346 , C12Y305/01098 , A61K2300/00 , C12N2310/3525
摘要： Methods are provided for reducing SIRT1 expression by administering a SIRT1 inhibitor. Also provided are methods for treating cardiovascular and metabolic disorders in a subject or delaying or preventing risk factors thereof through the reduction of SIRT1 expression. The present invention is also directed to methods of decreasing lipid levels in a subject or for preventing or delaying the onset of a rise in lipid levels in a subject, comprising administering to said subject a SIRT1 inhibitor.
摘要翻译：提供了通过施用SIRT1抑制剂来减少SIRT1表达的方法。还提供了通过降低SIRT1表达来治疗受试者的心血管和代谢紊乱或延缓或预防其风险因素的方法。本发明还涉及减少受试者中的脂质水平或用于预防或延迟受试者中脂质水平升高的发生的方法，包括向所述受试者施用SIRT1抑制剂。

7. 发明申请

WO2008157640A2 MICROFABRICATION METHODS FOR THE OPTIMAL PATTERNING OF SUBSTRATES 审中-公开
标题翻译：用于基板的最佳方案的微晶化方法
公开(公告)号：WO2008157640A2
公开(公告)日：2008-12-24
申请号：PCT/US2008/067402
申请日：2008-06-18
申请人： ILLUMINA, INC. , LEBL, Michal , HEINER, David, L. , ZHAO, Chanfeng , BARKER, David
发明人： LEBL, Michal , HEINER, David, L. , ZHAO, Chanfeng , BARKER, David
IPC分类号： B01J19/00 , C40B50/14
CPC分类号： C40B50/06 , B01J19/0046 , B01J2219/00317 , B01J2219/00497 , B01J2219/00585 , B01J2219/00596 , B01J2219/00605 , B01J2219/00648 , B01J2219/00659 , B01J2219/00677 , B01J2219/00722 , B01J2219/00725 , C40B40/06 , C40B50/14
摘要： The invention is directed to a method of fabricating a microarray. The method includes: (a) providing a substrate having at least two layers of different chemical reactivity, wherein a well in an outer layer exposes an inner layer; (b) contacting the substrate with a first reagent specifically reactive with the outer layer to produce a first modified layer; (c) contacting the substrate with a second reagent specifically reactive with the inner layer of the substrate to produce a modified inner layer, wherein the modified inner layer has a higher affinity for a biopolymer than the modified outer layer, and (d) depositing the biopolymer onto the modified inner layer within the well, wherein the higher affinity of the modified inner layer facilitates localization of the biopolymer onto the well. Methods of fabricating a microarray which include polishing a substrate or functionalizing a plurality of features with a reactive reagent also are provided. A method of fabricating a microarray which includes loading a plurality of discrete nanochannels is additionally provided.
摘要翻译：本发明涉及一种制造微阵列的方法。该方法包括：（a）提供具有不同化学反应性的至少两层的基材，其中外层中的孔暴露内层; （b）使所述基材与特定与外层反应的第一试剂接触以产生第一改性层; （c）使基材与第二试剂接触，所述第二试剂与基材的内层特异性反应以产生改性内层，其中改性内层对生物聚合物的亲和力高于改性外层，和（d）生物聚合物加入到孔内的改性内层上，其中改性内层的较高亲和力有利于将生物聚合物定位在孔上。还提供了制造微阵列的方法，其包括研磨底物或用反应试剂使多个特征功能化。另外提供了一种制造微阵列的方法，其包括加载多个离散的纳米通道。

8. 发明申请

WO2008019351A2 COMPOSITIONS AND THEIR USES DIRECTED TO DIACYLGLYCEROL ACYLTRANSFERASE 1 审中-公开
标题翻译：组合物及其用途指向二乙酰胆碱酯酶1
公开(公告)号：WO2008019351A2
公开(公告)日：2008-02-14
申请号：PCT/US2007/075297
申请日：2007-08-06
申请人： ISIS PHARMACEUTICALS, INC. , YU, Xiag-xian , BHANOT, Sanjay , MONIA, Brett, P.
发明人： YU, Xiag-xian , BHANOT, Sanjay , MONIA, Brett, P.
IPC分类号： A61K48/00
CPC分类号： C12N15/1137 , C12N2310/11 , C12Y203/0102
摘要： Disclosed herein are compounds, compositions and methods for modulating DGAT- I activity. Preferably, the expressionof DGAT-I from a nucleic acid is inhibited. Methods are provided for treating, ameliorating or treating liver fibrosis, either directly or by treating an underlying etiological factor. Preferably, the treatment, amelioration or prevention comprises administering a DGAT- I activity modulator.
摘要翻译：本文公开了调节DGAT-1活性的化合物，组合物和方法。优选地，来自核酸的DGAT-1的表达被抑制。提供了直接治疗或改善肝纤维化或通过治疗潜在病因的方法。优选地，治疗，改善或预防包括施用DGAT-1活性调节剂。

9. 发明申请

WO2007050777A2 METHODS AND COMPOSITIONS FOR DIAGNOSING LUNG CANCER WITH SPECIFIC DNA METHYLATION PATTERNS 审中-公开
标题翻译：用特异性DNA甲基化模式诊断肺癌的方法和组合物
公开(公告)号：WO2007050777A2
公开(公告)日：2007-05-03
申请号：PCT/US2006/041821
申请日：2006-10-25
申请人： ILLUMINA, INC. , FAN, Jian-Bing , BIBIKOVA, Marina
发明人： FAN, Jian-Bing , BIBIKOVA, Marina
IPC分类号： C12Q1/68 , G06F19/00
CPC分类号： C12Q1/6827 , C12Q1/6886 , C12Q2600/112 , C12Q2600/118 , C12Q2600/154 , C12Q2600/16 , C12Q2523/125
摘要： The present invention provides a method for identification of differentially methylated genomic CpG dinucleotide sequences within genomic target sequences that are associated with cancer in an individual by obtaining a biological sample comprising genomic DNA from the individual measuring the level or pattern of methylated genomic CpG dinucleotide sequences for two or more of the genomic targets in the sample, and comparing the level of methylated genomic CpG dinucleotide sequences in the sample to a reference level of methylated genomic CpG dinucleotide sequences, wherein a difference in the level or pattern of methylation of the genomic CpG dinucleotide sequences in the sample compared to the reference level identifies differentially methylated genomic CpG dinucleotide sequences associated with cancer. As disclosed herein, the methods of the invention have numerous diagnostic and prognostic applications. The methods of the invention can be combined with a miniaturized array platform that allows for a high level of assay multiplexing and scalable automation for sample handling and data processing. Also provided by the invention are genomic targets and corresponding nucleic acid probes that are useful in the methods of the invention as they enable detection of differentially methylated genomic CpG dinucleotide sequences associated with adenocarcenomas of the lung.
摘要翻译：本发明提供了通过获得包含来自个体的基因组DNA的生物样品来鉴定与个体癌症相关的基因组靶序列内的差异甲基化基因组CpG二核苷酸序列的方法，所述生物样品包含测量甲基化基因组CpG二核苷酸序列的水平或模式，样品中的两个或更多个基因组靶标，并将样品中甲基化的基因组CpG二核苷酸序列的水平与甲基化的基因组CpG二核苷酸序列的参考水平进行比较，其中基因组CpG二核苷酸的甲基化水平或模式的差异与参考水平相比，样品中的序列鉴定与癌症相关的差异甲基化的基因组CpG二核苷酸序列。如本文所公开的，本发明的方法具有许多诊断和预后应用。本发明的方法可以与微型阵列平台组合，其允许用于样品处理和数据处理的高水平的测定复用和可扩展的自动化。本发明还提供了可用于本发明方法的基因组靶和相应的核酸探针，因为它们能够检测与肺腺癌有关的差异甲基化的基因组CpG二核苷酸序列。

10. 发明申请

WO2004056966A2 METHODS OF INHIBITING GENE EXPRESSION BY RNA INTERFERENCE 审中-公开
标题翻译：通过RNA干扰抑制基因表达的方法
公开(公告)号：WO2004056966A2
公开(公告)日：2004-07-08
申请号：PCT/US2003/040948
申请日：2003-12-18
申请人： SALK INSTITUTE FOR BIOLOGICAL STUDIES , VERMA, Inder, M. , TISCORNIA, Gustavo , SINGER, Oded
发明人： VERMA, Inder, M. , TISCORNIA, Gustavo , SINGER, Oded
IPC分类号： C12N
CPC分类号： C12N15/111 , A61K48/00 , C12N15/86 , C12N2310/111 , C12N2310/14 , C12N2310/53 , C12N2330/30 , C12N2740/16043 , C12N2800/30 , C12N2830/002 , C12N2830/15 , C12N2830/38 , C12N2830/48 , C12N2830/50 , C12N2840/20
摘要： The invention provides a lentiviral vector capable of inhibiting the expression of at least one target gene. A lentiviral vector of the invention encompasses a first nucleic acid sequence derived from a target gene transcript and a second nucleic acid sequence corresponding to the reverse complement of said first nucleic acid sequence. A lentiviral vector of the invention capable of inhibiting the expression of a target gene is useful in therapeutic applications to inactivate disease-associated transcripts and thereby reduce the severity of inherited metabolic, infectious or malignant conditions. Methods for inhibiting one or more target genes in a cell as well as methods for producing a non-human mammal in which the expression of one or more target genes is inhibited also are provided by the present invention.
摘要翻译：本发明提供能够抑制至少一种靶基因表达的慢病毒载体。本发明的慢病毒载体包括衍生自靶基因转录物的第一核酸序列和对应于所述第一核酸序列的反向互补序列的第二核酸序列。能够抑制靶基因表达的本发明的慢病毒载体可用于灭活疾病相关转录物的治疗应用，从而降低遗传性代谢性，感染性或恶性病症的严重性。抑制细胞中一种或多种靶基因的方法以及抑制一种或多种靶基因表达的非人哺乳动物的制备方法也由本发明提供。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式